Emerging cell-cycle inhibitors for pancreatic cancer therapy

Bibliography

• Cancer Facts and Figures 2012. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf [Last accessed on 5 August 2012]
   Google Scholar
• Almhanna K, Philip PA. Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol 2011;12:111-25
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J clin Oncol 1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Casper E, Green M, Kelsen D, Phase II trial of gemcitabine (2,20-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6
   PubMed Web of Science ®Google Scholar
• Hruban RH, Goggins M, Parsons J, Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72
   PubMed Web of Science ®Google Scholar
• Evans JD SA, Johnson CD, A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001;85:1865-70
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Ranganathan S, Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003;21:1301-6
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P, Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Kayaleh OR, Goodwin JW, A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer. J Clin Oncol 2005;23(Suppl):4174
   Google Scholar
• Wolpin BM, Ryan DP, Abrams TA, Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. J Clin Oncol 2008;26:2210-13
   Google Scholar
• Xiong HQ, Rosenberg A, LoBuglio A, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-16
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Bobos M, Kalogera-Fountzila A, Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 2008;26:784-93
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Fogelman DR, Xiong HQ, Chang DZ, Final results of a bi-institution phase II study of gemcitabine, oxaliplatin, and bevacizumab for advanced pancreatic cancer [abstract 182]. In 2009 ASCO Gastrointestinal Cancers Symposium; 2009
   Google Scholar
• Kindler HL, Hollis D. A double-blind placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. In 2007 Gastrointestinal Cancers symposium; 2007
   Google Scholar
• Kindler HL, Stephenson J, Garbo LE, A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 2010;28: 15s (abstract 4035)
   PubMedGoogle Scholar
• Javle MM, Shroff RT, Bhosale P, Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol 2010;28: 15s (abstract 4039)
   Google Scholar
• Ogino T, Suzuki H, Yamasaki A, Evaluation of the hedgehog signaling pathway as a therapeutic target for dendritic cell-based immunotherapy against patients with cancer. J Clin Oncol 2010;28: 15s (e13061)
   Web of Science ®Google Scholar
• Ashworth A. Drug resistance caused by reversion mutation. Cancer Res 2008;68:10021-3
   PubMed Web of Science ®Google Scholar
• Boeck SH, Waldschmidt V, Kettner E, Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): a randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010;28: 18s (abstract LBA4011)
   PubMedGoogle Scholar
• Von Hoff DD, Borad M, Laheru D, SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study. J Clin Oncol 2009;27: 15s (abstract 4525)
   PubMedGoogle Scholar
• Hosein PJ, Gomez CM, Macintyre J, A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine-based therapy. In J Clin Oncol 2010 ASCO Gastrointestinal Cancer Symposium; 2010
   Google Scholar
• Malumbres M. Physiological relevance of cell cycle kinases. Physiol Rev 2011;91:973-1007
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7
   PubMed Web of Science ®Google Scholar
• Von Hoff DD. What's new in pancreatic cancer treatment pipeline? Best Pract Res Clin Gastroenterol 2006;20:315-26
   PubMed Web of Science ®Google Scholar
• Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res 2004;10:6598-605
   PubMed Web of Science ®Google Scholar
• Yue H, Jiang HY. Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study. World J Gastroenterol 2005;11:5057-60
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66
   PubMed Web of Science ®Google Scholar
• Poch B, Gansauge F, Schwarz A, Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression. Pancreas 2001;23:280-7
   PubMed Web of Science ®Google Scholar
• Wang JC, Thiere M, Henne-Bruns D, Inhibition of pancreatic cancer cell growth in vivo using a tetracycline-inducible cyclin D1 antisense expression system. Pancreas 2012; Epub ahead of print
   Google Scholar
• Gansauge S, Gansauge F, Ramadani M, Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-7
   PubMed Web of Science ®Google Scholar
• Kornmann M, Ishiwata T, Itakura J, Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998;55:363-9
   PubMed Web of Science ®Google Scholar
• Eggers JP, Grandgenett PM, Collisson EC, Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clin Cancer Res 2011;17:6140-50
   PubMed Web of Science ®Google Scholar
• Feldmann G, Mishra A, Hong SM, Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010;70:4460-9
   PubMed Web of Science ®Google Scholar
• Archambault V, Carmena M. Polo-like kinase-activating kinases: aurora A, Aurora B and what else? Cell Cycle 2012;11:1490-5
   PubMed Web of Science ®Google Scholar
• Hao D, Chu Q, Welch S, A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor. In Oncol JC (ed) 2012. ASCO Annual Meeting; 2012
   Google Scholar
• Green MR, Woolery JE, Mahadevan D. Update on aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov 2011;6:291-307
   PubMed Web of Science ®Google Scholar
• Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5:429-40
   PubMed Web of Science ®Google Scholar
• Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008;34:175-82
   PubMed Web of Science ®Google Scholar
• Gray PJ Jr, Bearss DJ, Han H, Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004;3:641-6
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36
   PubMed Web of Science ®Google Scholar
• Spankuch B, Heim S, Kurunci-Csacsko E, Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006;66:5836-46
   PubMed Web of Science ®Google Scholar
• Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-108
   PubMed Web of Science ®Google Scholar
• Tibes R, Jimeno A, Von Hoff DD, Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125. In ASCO Meeting Abstracts; 2008
   Google Scholar
• Bahleda R, Martinez-Garcia A, Varga A, First-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule. In Oncol JC (ed) 2012. ASCO Annual Meeting; 2012
   Google Scholar
• Shapiro GI, Bannerji R, Small K, A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies. In Oncol JC (ed) ASCO 2008 Annual Meeting; 2008
   Google Scholar
• Nemunaitis J, Steinberg SM, Rosenberg MA, A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. In Oncol JC (ed) 2009 ASCO Annual Meeting; 2009
   Google Scholar
• Scott EN, Thomas AL, Molife LR, A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. Cancer Chemother Pharmacol 2009;64:425-9
   PubMed Web of Science ®Google Scholar
• Olmos D, Ventura AA, Sharma R, Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. In Oncol JC (ed) 2009 ASCO Annual Meeting; 2009
   Google Scholar
• Ma WW, Freas A, Dy GK, Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. In Oncol JC (ed) 2011 ASCO Annual Meeting; 2011
   Google Scholar
• Schellens JHM, Shapiro G, Pavlick AC, Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. In Oncol JC (ed) 2011 ASCO Annual Meeting; 2011
   Google Scholar
• Daud A, Springett GM, Mendelson DS, A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. In Oncol JC (ed) 2010 ASCO Annual Meeting; 2010
   Google Scholar
• Karp JE, Garrett-Mayer EL, Estey EH, Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Burdette-Radoux S, Tozer RG, Lohmann RC, Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004;22:315-22
   PubMed Web of Science ®Google Scholar
• Grendys EC Jr, Blessing JA, Burger R, A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:249-53
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Lacy MQ, Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006;91:390-3
   PubMed Web of Science ®Google Scholar
• Laffranchi B, De Jonge MJ, Bajetta E, Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers. In Oncol JC (ed) 2010 ASCO Annual Meeting; 2010
   Google Scholar
• Rizzolio F, Tuccinardi T, Caligiuri I, CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 2010;11:279-90
   PubMed Web of Science ®Google Scholar
• Kreutzer JN, Ruzzene M, Guerra B. Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer 2010;10:440
   PubMed Web of Science ®Google Scholar
• Baughn LB, Di Liberto M, Wu K, A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66:7661-7
   PubMed Web of Science ®Google Scholar
• Walsby E, Lazenby M, Pepper C, The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 2011;25:411-19
   PubMed Web of Science ®Google Scholar
• Iseki H, Ko TC, Xue XY, A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J Gastrointest Surg 1998;2:36-43
   PubMedGoogle Scholar
• Dickson MA, Carvajal G, Shah MA, A phase I study of FOLFOX administered with flavopiridol (F) in patients with refractory solid tumors. In Oncol JC (ed) 2008 ASCO Annual Meeting; 2008
   Google Scholar
• Rathkopf D, Dickson MA, Feldman DR, Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009;15:7405-11
   PubMed Web of Science ®Google Scholar
• Dickson MA, Shah MA, Rathkopf D, A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 2010;66:1113-21
   PubMed Web of Science ®Google Scholar
• Fekrazad HM, Verschraegen CF, Royce M, A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am J Clin Oncol 2010;33:393-7
   PubMed Web of Science ®Google Scholar
• George S, Kasimis BS, Cogswell J, Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008;9:160-5
   PubMed Web of Science ®Google Scholar
• Dickson MA, Rathkopf D, Grant S, Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors. In Oncol JC (ed) 2010 ASCO Annual Meeting; 2010
   Google Scholar
• Carvajal RD, Tse A, Shah MA, A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 2009;9:404-9
   PubMed Web of Science ®Google Scholar
• Meinhart A, Kamenski T, Hoeppner S, A structural perspective of CTD function. Genes Dev 2005;19:1401-15
   PubMed Web of Science ®Google Scholar
• Feldmann G, Mishra A, Bisht S, Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011;12:598-609
   PubMed Web of Science ®Google Scholar
• de Bruijn P, Moghaddam-Helmantel IM, de Jonge MJ, Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 2009;50:977-82
   PubMed Web of Science ®Google Scholar
• Siemeister G, Luecking U, Wagner C, Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother 2006;60:269-72
   PubMed Web of Science ®Google Scholar
• Albanese C, Alzani R, Amboldi N, Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther 2010;9:2243-54
   PubMed Web of Science ®Google Scholar
• Bahleda R, Spreafico A, Soria J, Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors. In Oncol JC (ed) 2010 ASCO Annual Meeting; 2010
   Google Scholar
• Mendoza N, Fong S, Marsters J, Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003;63:1020-4
   PubMed Web of Science ®Google Scholar
• Canela N, Orzaez M, Fucho R, Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J Biol Chem 2006;281:35942-53
   PubMed Web of Science ®Google Scholar
• Bagella L, Sun A, Tonini T, A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 2007;26:1829-39
   Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Taylor S, Peters JM. Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 2008;20:77-84
   PubMed Web of Science ®Google Scholar
• Carducci MA, O'Brien SM, Paller CJ, First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors. In Oncol JC (ed) 2012 ASCO Annual Meeting; 2012
   Google Scholar
• Dumez H, Gombos A, Schoffski P, Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. In Oncol JC (ed) 2012 ASCO Annual Meeting; 2012
   Google Scholar
• Mazumdar A, Henderson YC, El-Naggar AK, Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009;31:625-34
   PubMed Web of Science ®Google Scholar
• Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3:51-62
   PubMed Web of Science ®Google Scholar
• Squire CJ, Dickson JM, Ivanovic I, Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 2005;13:541-50
   PubMed Web of Science ®Google Scholar
• Bridges KA, Hirai H, Buser CA, MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011;17:5638-48
   PubMed Web of Science ®Google Scholar
• Hirai H, Arai T, Okada M, MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66
   PubMed Web of Science ®Google Scholar
• http://www.clinicaltrials.gov
   Google Scholar
• Konecny GE, Winterhoff B, Kolarova T, Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 2011;17:1591-602
   PubMed Web of Science ®Google Scholar
• Perini RF, DeMichele A, Vaughn DJ, Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1. In Oncol JC (ed) 2011 ASCO Annual Meeting; 2011
   Google Scholar
• Goto H, Izawa I, Li P, Novel regulation of checkpoint kinase 1: is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Chandana S, Mahadevan D. Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype? Expert Rev Mol Med 2009;11:e34
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404
   PubMed Web of Science ®Google Scholar
• Berthet C, Aleem E, Coppola V, Cdk2 knockout mice are viable. Curr Biol 2003;13:1775-85
   PubMed Web of Science ®Google Scholar
• Santamaria D, Barriere C, Cerqueira A, Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007;448:811-15
   PubMed Web of Science ®Google Scholar
• Wang L, Wang J, Blaser BW, Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007;110:2075-83
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, Marimastat as firstline therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-55
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, A double-blind placebocontrolled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm J, Dancey J, Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302
   PubMed Web of Science ®Google Scholar
• Philip PA, Fenoglio-Preiser M, Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol 2007;25: 18s (abstract LBA 4509)
   PubMedGoogle Scholar
• Stone A, Sutherland RL, Musgrove EA. Inhibitors of cell cycle kinases: recent advances and future prospects and cancer therapeutics. Crit Rev Oncog 2012;17:175-98
   PubMedGoogle Scholar